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Abstract The glucose transport proteins (GLUT1 and GLUT4)
facilitate glucose transport into insulin-sensitive cells. GLUT1 is
insulin-independent and is widely distributed in different tissues.
GLUT4 is insulin-dependent and is responsible for the majority
of glucose transport into muscle and adipose cells in anabolic
conditions. We suggest the hypothesis that insulin resistance is
dependent on whether glucose is entering through GLUT1 or
GLUT4 and on the two functional compartments of glucose
6-phosphate formation within the cell. Glucose entering the
muscle cell through GLUT4 and phosphorylated by hexokinase
II is mainly directed to glycogen synthesis and glycolysis. If
glucose is entering through GLUT1 and phosphorylated by
hexokinase I, the glucose 6-phosphate so formed is available for
all metabolic pathways, including the hexosamine pathway.
Hexosamines have a negative feedback effect on GLUT4, and
reduced GLUT4 activity decreases insulin-mediated glucose
uptake. Thus, insulin-independent glucose transport through
GLUT1 can meet the basal needs of the muscle cell. If glucose
entrance through GLUT1 and the activation of the hexosamine
pathway is abundant, it can decrease the insulin-mediated
glucose transport through GLUT4 leading to insulin resistance.
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1. Phylogeny and structure of glucose transport proteins
Glucose is a vital fuel for microorganisms and nearly all cell
types in humans. Glucose transport into the cell is catalyzed
by transport proteins. Even Escherichia coli, which does not
have insulin, has two proton-sugar symporters, proton-xylose
and proton-arabinose. They share 20^25% amino acid se-
quence identity with mammalian glucose transporters [1]. In
mammalian cells there are at least six facilitative glucose
transporters, which are products of a gene family and have
speci¢c functions and sites of expression [2]. Glucose trans-
porter 1 (GLUT1) is the predominant facilitative glucose
transporter and it is widely distributed in di¡erent tissues.
GLUT1 is highly conserved with 98% identity in the amino
acid sequence between humans and the rat [2]. GLUT4 is
insulin-sensitive and it is the predominant glucose transporter
in the muscle and adipose tissue. There is 95% sequence iden-
tity between human and rat GLUT4 [2], whereas human
GLUT1 and GLUT4 have 65% identity.
GLUT1 seems to be coupled with hexokinase I, and
GLUT4 with hexokinase II (Fig. 1). Fetal muscle expresses
GLUT1 and hexokinase I [3,4], whereas GLUT4 and hexoki-
nase II become predominant in the muscle postnatally [3,4].
The appearances of GLUT4 and hexokinase II in skeletal
muscle are coordinated and concomitant with insulin sensitiv-
ity in young rats [3,4]. Insulin increases the transcription of
muscle hexokinase II, but has no e¡ect on hexokinase I [4^6],
which is ubiquitous and is found in almost all cells [5].
2. Why insulin-dependent and -independent transporters?
GLUT4 coupled to hexokinase II facilitates the metabolism
or storage of glucose in the muscle and in the adipose tissue in
insulin-stimulated conditions, such as after a meal. Another
example of the coupling of GLUT4 and insulin action is a
well trained athlete, in whom elevated muscle GLUT4 content
is associated with increased insulin-stimulated glucose dis-
posal (insulin sensitivity) [7]. Thus, GLUT4 is insulin-depend-
ent and mediates the insulin-stimulated glucose disposal in
muscle tissue.
GLUT1 protein may be responsible, at least in part, for the
constitutive, insulin-independent glucose uptake in all cells
including muscle [2]. In addition to its traditional role, muscle
tissue has other functions, such as a role in immunology. The
amino acid glutamine is synthesized from glucose in the skel-
etal muscle [8,9]. Continuous maintenance of a su⁄cient glu-
tamine concentration in the blood is necessary for the proper
functioning of the immune system and survival [10]. This is
especially the case during infections, when macrophages need
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Fig. 1. Glucose transport into muscle cell is mediated by two glu-
cose transport proteins: insulin-independent GLUT1 and insulin-de-
pendent GLUT4. If glucose is transported though the GLUT1 path-
way, it is further metabolized by hexokinase I via glucose 6-
phosphate (G-6-P) and fructose 6-phosphate (F-6-P) also to hexos-
amines. These can reduce GLUT4 activity resulting in a decrease in
insulin-mediated glucose disposal or insulin resistance.
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glutamine [10]. Intramuscular glucose is used for RNA syn-
thesis through the pentose phosphate pathway, and through
the hexosamine pathway for the synthesis of glycoproteins
and for the transcriptional control of some genes [11]. These
metabolic reactions need a continuous fuel £ux that is inde-
pendent of nutritional status and insulin secretion.
3. Overexpression of GLUT1 and GLUT4
In transgenic mice overexpression of GLUT1 in skeletal
muscle leads to fasting hypoglycemia, increased glucose up-
take without a rise in plasma insulin and diminishes the blood
glucose increment after an oral glucose load [12]. In addition,
in these animals muscle glycogen and free glucose concentra-
tions are elevated [13]. However, insulin-stimulated glucose
uptake is reduced by nearly 50% [14,15]. GLUT4 overexpres-
sion in mice leads to fasting hypoglycemia, reduced rise in
blood glucose after an oral glucose load and elevated muscle
glycogen concentrations [16]. Insulin sensitivity in these ani-
mals is increased by 40^50% [14,15]. Thus, glucose entrance
into muscle cells through overexpressed GLUT1 leads to in-
sulin resistance, whereas overexpression of GLUT4 enhances
insulin sensitivity.
4. Hexosamines ^ a signal between GLUT1 and GLUT4
In healthy rats, the infusion of fatty acids, glucosamine or
uridine, or hyperglycemia as such all increase the muscle
UDP-N-acetylglucosamine concentration, which is an index
of glucose metabolism through the hexosamine pathway.
Each of these factors also causes insulin resistance and re-
duces insulin-stimulated glycogen synthesis in muscle cells
[17]. When glucosamine and uridine are infused simultane-
ously they have an additive e¡ect in increasing muscle
UDP-N-acetylglucosamine levels and in causing insulin resist-
ance [18]. A rise in glucosamine availability increases glucos-
amine incorporation into skeletal muscle GLUT4-containing
vesicles reducing their activity [18]. In GLUT1 transgenic mice
the 50% decrease in insulin sensitivity is associated with a rise
in muscle UDP hexosamines. Thus, a rise in muscle hexos-
amine concentration causes insulin resistance, probably
through a negative feedback e¡ect on GLUT4 vesicles (Fig.
1).
In contrast, in GLUT4 transgenic mice with 40% increase in
insulin-stimulated glucose uptake the muscle hexosamine con-
centration remains unaltered [15]. Similarly, in rats a 6 h
hyperinsulinemic stimulation of glucose uptake has no e¡ect
on muscle UDP-N-acetylglucosamine concentration despite
increased muscle glucose uptake [19]. Thus, when the in-
creased glucose uptake in these conditions probably occurs
through the insulin-sensitive GLUT4, it has no in£uence on
muscle hexosamine concentration.
In healthy relatives of type 2 diabetic patients insulin-stimu-
lated glucose uptake is decreased, but their glucose e¡ective-
ness (as determined by an intravenous glucose tolerance test)
is increased [20]. It is possible that the glucose uptake, which
is stimulated by acute hyperglycemia, is mediated mainly
through GLUT1. Thus, the predominance of glucose trans-
port between GLUT4 and GLUT1 may change depending on
the conditions. There are no data on whether changes in the
glucose transport routes occur similarly in the fasting state as
they seem to happen under stimulated conditions.
5. Insulin resistance in obesity, in£ammation or hyperglycemia
In humans insulin resistance is caused by three main fac-
tors: obesity [21], in£ammation or infections [22,23] and hy-
perglycemia per se [24]. Obesity is often associated with ele-
vated serum free fatty acid concentrations and enhanced lipid
oxidation [25]. This may cause insulin resistance via inhibition
of pyruvate dehydrogenase and phosphofructokinase, direct-
ing glucose into the hexosamine pathway [17]. In£ammation is
characterized by increased concentrations of cytokines, such
as tumor necrosis factor K (TNF-K) or interleukin (IL) 1.
Cytokines downregulate GLUT4, upregulate GLUT1 [26,27]
and stimulate hexose transport in ¢broblasts or in rat adipose
cells [28^30]. Hyperglycemia increases glucose £ux into muscle
cell by the mass action e¡ect. This e¡ect is insulin-independent
and therefore probably occurs through GLUT1. Obese and
type 2 diabetic patients also have a reduced insulin-induced
expression of hexokinase II [6]. Thus, the common feature for
the insulin resistance induced by obesity, in£ammation and
infection or hyperglycemia is enhanced glucose transport
through GLUT1 and availability for the formation of hexos-
amines. These can reduce muscle GLUT4 and hexokinase II
activity leading to a decrease in insulin-mediated glucose
transport (Fig. 1). Troglitazone, which improves insulin sen-
sitivity in type 2 diabetic patients, can prevent hyperglycemia-
induced but not glucosamine-induced insulin resistance, sug-
gesting that it has an e¡ect somewhere between GLUT1 and
hexosamines (Fig. 1) [31].
Insulin resistance is a common factor in both type 2 dia-
betic patients and patients with cardiovascular disease [32].
Type 2 diabetic patients are characterized by chronically ele-
vated concentrations of acute-phase serum proteins and cyto-
kines, such as haptoglobin, K1-acid glycoprotein, C-reactive
protein or IL-6 [33,34]. Similar results have been reported also
in glucose intolerance [33]. There is increasing evidence that a
chronic in£ammation contributes to the development of athe-
rosclerosis [35]. In both conditions increased cytokine action
can lead to glucose transport through GLUT1 and the hexos-
amine pathway reducing the insulin-mediated glucose trans-
port through GLUT4.
Nitric oxide (NO) may also play a role. The NO donor
sodium nitroprusside (SNP) stimulates rat skeletal muscle glu-
cose transport, and increases cell surface GLUT4 concentra-
tion [36]. The e¡ects of SNP and insulin on glucose transport
are additive at physiological insulin concentrations [37]. How-
ever, production of NO by the cytokine-inducible NO syn-
thase in rat skeletal muscle is associated with decreased insu-
lin-stimulated glucose transport [38]. Also a high glucose
concentration, which reduces insulin-stimulated glucose up-
take in muscle, increases NO generation in human aortic en-
dothelial cells [39]. In L6 myocytes the cytokine-induced in-
crease in glucose uptake is totally prevented by the inhibition
of NO synthase [40]. Furthermore, recent in vitro data suggest
that thiazolidinediones, insulin-sensitizing agents, inhibit the
production of in£ammatory cytokines as well as downstream
markers of in£ammation such as NO elaborated by monocytic
cells [41,42]. In humans recent data suggest that NO levels are
elevated in ¢rst-degree relatives of type 2 diabetic patients
[43]. These patients have a reduced insulin-mediated glucose
disposal (via GLUT4) and an increased glucose e¡ectiveness
(via GLUT1?) [20].
It is thus possible that NO is involved in glucose transport
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via both GLUT4 and GLUT1 pathways. The transport via
GLUT1 may involve increased production of NO caused by
factors such as cytokines or hyperglycemia. If transport via
GLUT1 is stimulated, it can reduce glucose transport via
GLUT4. If the contribution of deleterious NO is reduced,
as occurs after in£ammation or during thiazolidinedione ther-
apy, this can enhance insulin-stimulated transport through
GLUT4.
This hypothesis can also explain why impaired glucose tol-
erance or insulin resistance paradoxically may be associated
with fasting hypoglycemia. Chronic IL-1L infusion in rats
resulted in fasting hypoglycemia and elevated blood glucose
levels in response to oral glucose [44]. Anabolic steroids can
induce the production of in£ammatory cytokines IL-1L and
TNF-K from human peripheral blood lymphocytes [45], and
methanedienone administration in humans can lower fasting
blood glucose concentration, but reduce both oral and intra-
venous glucose tolerance [46]. These observations can be ex-
plained by increased glucose transport through GLUT1 in a
fasting state, and decreased GLUT4 action during hyperinsu-
linemia.
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